In a study of 300 COVID-19 patients,
the time to improvement across 12 symptoms was reduced by 4 days compared to placebo. Within 16 hours of the initial dose, viral load decreased by 92% compared to placebo, demonstrating clear efficacy.
No serious adverse events were observed, and there were no significant differences from placebo in mild to moderate adverse events, confirming its safety profile.
